Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Somatostatin Analogs Market by Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Somatostatin Analogs Market by Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 130090 3300 Pharma & Healthcare 377 250 Pages 4.9 (49)

The global somatostatin analogs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of endocrine disorders and rising demand for somatostatin analogs in emerging economies such as China and India. Octreotide, lanreotide, pasireotide are the three types of somatostatin analogs available in the market. Octreotide is used for treating acromegaly and carcinoid syndrome whereas lanreotide and pasireotide are used for treating neuroendocrine tumor (NET) patients with cushing syndrome or acromegaly respectively. The application segment includes acromegaly, carcinoid syndrome, neuroendocrine tumor (NET), cushing syndrome which are further classified into North America, Latin America, Europe, Asia Pacific and Middle East & Africa regions respectively.

Some Of The Growth Factors Of This Market:

  1. The Somatostatin Analogs market is driven by the increasing prevalence of chronic diseases such as diabetes and obesity, which are major risk factors for cancer.
  2. Increasing awareness about the benefits of Somatostatin Analogs in cancer treatment will drive the growth of this market.
  3. Increasing number of clinical trials on Somatostatin Analogs will provide opportunities for new product launches and innovations in this market.
  4. Growing geriatric population base will also fuel the growth of this market.

Industry Growth Insights published a new data on “Somatostatin Analogs Market”. The research report is titled “Somatostatin Analogs Market research by Types (Octreotide, Lanreotide, Pasireotide), By Applications (Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others), By Players/Companies Novartis, Peptron, Chiasma, Ipsen Biopharmaceutical, ...”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Somatostatin Analogs Market Research Report

By Type

Octreotide, Lanreotide, Pasireotide

By Application

Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others

By Companies

Novartis, Peptron, Chiasma, Ipsen Biopharmaceutical, ...

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Somatostatin Analogs Industry Outlook

Global Somatostatin Analogs Market Report Segments:

The global Somatostatin Analogs market is segmented on the basis of:


Octreotide, Lanreotide, Pasireotide

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Novartis
  2. Peptron
  3. Chiasma
  4. Ipsen Biopharmaceutical
  5. ...

Global Somatostatin Analogs Market Overview

Highlights of The Somatostatin Analogs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Octreotide
    2. Lanreotide
    3. Pasireotide
  1. By Application:

    1. Acromegaly
    2. Carcinoid Syndrome
    3. Neuroendocrine Tumor
    4. Cushing Syndrome
    5. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Somatostatin Analogs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Somatostatin Analogs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Somatostatin analogs are medications that are similar to somatostatin, but they have different chemical structures. These drugs can be used to treat a variety of conditions, including diabetes and obesity.

Some of the key players operating in the somatostatin analogs market are Novartis, Peptron, Chiasma, Ipsen Biopharmaceutical.

The somatostatin analogs market is expected to grow at a compound annual growth rate of 5.5%.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Somatostatin Analogs Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Somatostatin Analogs Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Somatostatin Analogs Market - Supply Chain
   4.5. Global Somatostatin Analogs Market Forecast
      4.5.1. Somatostatin Analogs Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Somatostatin Analogs Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Somatostatin Analogs Market Absolute $ Opportunity

5. Global Somatostatin Analogs Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Somatostatin Analogs Market Size and Volume Forecast by Type
      5.3.1. Octreotide
      5.3.2. Lanreotide
      5.3.3. Pasireotide
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Somatostatin Analogs Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Somatostatin Analogs Market Size and Volume Forecast by Application
      6.3.1. Acromegaly
      6.3.2. Carcinoid Syndrome
      6.3.3. Neuroendocrine Tumor
      6.3.4. Cushing Syndrome
      6.3.5. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Somatostatin Analogs Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Somatostatin Analogs Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Somatostatin Analogs Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Somatostatin Analogs Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Somatostatin Analogs Demand Share Forecast, 2019-2029

9. North America Somatostatin Analogs Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Somatostatin Analogs Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Somatostatin Analogs Market Size and Volume Forecast by Application
      9.4.1. Acromegaly
      9.4.2. Carcinoid Syndrome
      9.4.3. Neuroendocrine Tumor
      9.4.4. Cushing Syndrome
      9.4.5. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Somatostatin Analogs Market Size and Volume Forecast by Type
      9.7.1. Octreotide
      9.7.2. Lanreotide
      9.7.3. Pasireotide
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Somatostatin Analogs Demand Share Forecast, 2019-2029

10. Latin America Somatostatin Analogs Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Somatostatin Analogs Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Somatostatin Analogs Market Size and Volume Forecast by Application
      10.4.1. Acromegaly
      10.4.2. Carcinoid Syndrome
      10.4.3. Neuroendocrine Tumor
      10.4.4. Cushing Syndrome
      10.4.5. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Somatostatin Analogs Market Size and Volume Forecast by Type
      10.7.1. Octreotide
      10.7.2. Lanreotide
      10.7.3. Pasireotide
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Somatostatin Analogs Demand Share Forecast, 2019-2029

11. Europe Somatostatin Analogs Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Somatostatin Analogs Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Somatostatin Analogs Market Size and Volume Forecast by Application
      11.4.1. Acromegaly
      11.4.2. Carcinoid Syndrome
      11.4.3. Neuroendocrine Tumor
      11.4.4. Cushing Syndrome
      11.4.5. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Somatostatin Analogs Market Size and Volume Forecast by Type
      11.7.1. Octreotide
      11.7.2. Lanreotide
      11.7.3. Pasireotide
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Somatostatin Analogs Demand Share, 2019-2029

12. Asia Pacific Somatostatin Analogs Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Somatostatin Analogs Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Somatostatin Analogs Market Size and Volume Forecast by Application
      12.4.1. Acromegaly
      12.4.2. Carcinoid Syndrome
      12.4.3. Neuroendocrine Tumor
      12.4.4. Cushing Syndrome
      12.4.5. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Somatostatin Analogs Market Size and Volume Forecast by Type
      12.7.1. Octreotide
      12.7.2. Lanreotide
      12.7.3. Pasireotide
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Somatostatin Analogs Demand Share, 2019-2029

13. Middle East & Africa Somatostatin Analogs Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Somatostatin Analogs Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Somatostatin Analogs Market Size and Volume Forecast by Application
      13.4.1. Acromegaly
      13.4.2. Carcinoid Syndrome
      13.4.3. Neuroendocrine Tumor
      13.4.4. Cushing Syndrome
      13.4.5. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Somatostatin Analogs Market Size and Volume Forecast by Type
      13.7.1. Octreotide
      13.7.2. Lanreotide
      13.7.3. Pasireotide
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Somatostatin Analogs Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Somatostatin Analogs Market: Market Share Analysis
   14.2. Somatostatin Analogs Distributors and Customers
   14.3. Somatostatin Analogs Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Novartis Overview Financials Developments Strategic Outlook
      14.4.2. Peptron Overview Financials Developments Strategic Outlook
      14.4.3. Chiasma Overview Financials Developments Strategic Outlook
      14.4.4. Ipsen Biopharmaceutical Overview Financials Developments Strategic Outlook
      14.4.5. ... Overview Financials Developments Strategic Outlook
      14.4.6. COMPANY6 Overview Financials Developments Strategic Outlook
      14.4.7. COMPANY7 Overview Financials Developments Strategic Outlook
      14.4.8. COMPANY8 Overview Financials Developments Strategic Outlook
      14.4.9. COMPANY9 Overview Financials Developments Strategic Outlook
      14.4.10. COMPANY 10 Overview Financials Developments Strategic Outlook
      14.4.11. COMPANY 11 Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us